A Phase I Open-label Study of Selinexor with Paclitaxel and Carboplatin in Patients with Advanced Ovarian or Endometrial Cancers

PURPOSE: Selinexor, a selective inhibitor of nuclear export, monotherapy causes nuclear accumulation of tumor-suppressor proteins and has anti-tumor activity in ovarian and endometrial cancers. The safety and tolerability of oral selinexor plus intravenous carboplatin and paclitaxel chemotherapy (se...

Full description

Saved in:
Bibliographic Details
Published in:Gynecol Oncol
Main Authors: Rubinstein, Maria M., Grisham, Rachel N., Cadoo, Karen, Kyi, Chrisann, Tew, William P., Friedman, Claire F., O’Cearbhaill, Roisin E., Zamarin, Dmitriy, Zhou, Qin, Iasonos, Alexia, Nikolovski, Ines, Xu, Hongmei, Soldan, Krysten N., Caird, Imogen, Martin, Madhuri, Guillen, Joyce, Eid, Khalil T., Aghajanian, Carol, Makker, Vicky
Format: Artigo
Language:Inglês
Published: 2020
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7779742/
https://ncbi.nlm.nih.gov/pubmed/33139041
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2020.10.019
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items